# EINPRESSWIRE

Digital Neuro Biomarkers Market to Reach USD 4592.14 Million by 2032 | SNS Insider

Rising Neurological Disorders and Technological Innovations Drive Market Growth at 25.96% CAGR

AUSTIN, TX, UNITED STATES, February 21, 2025 /EINPresswire.com/ -- According to a new research report by SNS Insider, the Digital Neuro Biomarkers Market was valued at USD 538.96 million in 2023 and is projected to reach USD 4592.14 million by 2032, growing at a CAGR of 25.96% during the forecast period 2024-2032. This

DIGITAL NEURO BIOMARKERS MARKET

MARKET STASTISTICS

MARKET SIZE 2023	CAGR 2024-2032	MARKET SIZE 2032
$ 538.96 MN	25.96%	$ 4592.14 MN

SEGMENT ANALYSIS
> By Type
The wearable segment dominated the market with the largest market share of 38% in 2023

REGIONAL ANALYSIS
In 2023, North America dominated the market for digital neuro biomarkers with a share of 35% of the total market

KEY PLAYERS
neurametrix   koneksa   altoida

source: www.snsinsider.com

Digital Neuro Biomarkers Market

rapid growth is fueled by the increasing prevalence of neurological diseases, technological advancements, and the rising need for personalized medicine.

The rising incidence of Alzheimer's, Parkinson's, and psychiatric disorders has significantly increased the demand for digital neuro biomarkers. Advances in wearable technologies, mobile health applications, and AI-driven analytics are enhancing real-time monitoring and early diagnosis of neurological conditions, leading to better disease management and treatment outcomes.

Get a Free Sample Report@ https://www.snsinsider.com/sample-request/5498

Key Players in Digital Neuro Biomarkers Market
• Altoida Inc. (Neuro Motor Index, Digital Cognitive Assessment Platform)
• Koneksa (Koneksa Compare, Mobile Neurocognitive Tests)
• Biogen Inc. (MS Performance Test, CogEval)
• Roche (Navify Algorithm Suite, Remote Patient Monitoring)
• NeuraMetrix (Typing Biometrics, NeuraMetrix Dashboard)
• Merck KGaA (Syntropy, Digital Biomarker Discovery)
• Linus Health (Digital Cognitive Assessment, Brain Health Platform)
• Neurotrack Technologies, Inc. (Memory Health Program, Eye Tracking Assessment)
• Empatica Inc. (EmbracePlus, Aura)

- Eyenuk (EyeArt AI System, EyeMark)
- BioSensics (PAMSys, LEGSys)
- ActiGraph LLC (CentrePoint Insight Watch, ActiLife Software)
- Aural Analytics (Speech Vitals, A2E Platform)
- Sonde Health, Inc. (Sonde Mental Fitness, Sonde Respiratory
- Quibim (QP-Brain, QP-Prostate)
- IXICO plc (TrialTracker, Assessa)
- Huma (Disease Agnostic Platform, Digital Biomarker Discovery)
- Feel Therapeutics (Feel Emotion Sensor, Digital Therapeutics Platform)
- Brainomix (e-Stroke Suite, e-CTA)
- Kinsa Inc. (Kinsa Smart Thermometers, HealthWeather)

By Type, the wearable segment dominated the digital neuro biomarkers market with 38% market share in 2023

The segment's dominance is because it can offer real-time, continuous monitoring of neurological conditions. Smartwatches, fitness trackers, and EEG headbands that are integrated with digital biomarkers enable smooth tracking of brain activity, movement patterns, and cognitive functions. The wearables improve early disease detection and symptom management for Parkinson's and Alzheimer's. Moreover, their widespread adoption of personalized healthcare solutions, remote patient monitoring, and clinical trials also aided greatly in establishing their market superiority. The reduction in cost, as well as the ease of use of wearables, have also fueled their broad acceptance. Further, strategic partnerships between technology firms and healthcare providers also expedited development in wearable neuro biomarker technology.

The mobile-based application segment will witness the fastest growth in the forecast years because of growing smartphone penetration and the expansion of demand for affordable, remote monitoring solutions. Mobile applications make it possible to monitor symptoms, cognitive function, and disease in real-time through patients, making patient engagement and healthcare facility pressure more manageable. Technological advancements in AI-powered analytics and cloud infrastructure further boost mobile applications' function, leading to widespread use within clinical and homecare environments. The capability of gathering high-frequency, real-time data at low cost makes apps based on the mobile platform an attractive option for healthcare providers. Moreover, policies encouraging digital health and telemedicine by governments also further fuel the growth of the segment.

By Clinical Practice, the diagnostic psychiatric digital biomarkers segment dominated the market with around 28% market share in 2023.

Clinical Practice is increasing demand for precise and early identification of psychiatric as well as neurological disorders. Since conditions like depression, schizophrenia, and bipolar disorder are on the rise, doctors have made digital biomarkers the top priority to accurately and precisely

diagnose. Artificial intelligence-based diagnostics, wearable devices, and smartphone applications have facilitated real-time measurements, less dependent on subjective clinical rating. Also, pharmaceutical and research organizations are adopting diagnostic digital biomarkers in clinical trials to accelerate drug development effectiveness. Increased sensitivity towards mental wellness, as well as governmental approval for digital diagnostics, has added further thrust to the leadership position of the segment in the industry.

The monitoring psychiatric digital biomarkers segment is expected to have the fastest growth during the forecast period because continuous remote monitoring is becoming a greater priority. Digital biomarkers offer important information on treatment response, disease progression, and symptom change in psychiatric disorders such as anxiety and PTSD. Wearables and mobile applications allow real-time monitoring of physiological and behavioral parameters, enhancing long-term care and decreasing hospital visits. In addition, improvements in machine learning and AI have fueled predictive analytics, permitting early intervention and tailored treatment plans. Integration of remote patient monitoring within mental health initiatives and increased telemedicine uptake are some of the primary drivers fueling this segment's high growth rate.

End Use, the healthcare companies segment dominated the market in 2023 with the highest market share.

The segment's dominance given its large involvement in creating, combining, and implementing digital biomarker solutions for managing neurological disease. Pharmaceutical firms, biotech companies, and medical device companies are investing a lot in R&D to develop early diagnosis, real-time tracking, and tailored treatment methods. Also, the growing usage of AI-driven analytics, wearable tech, and mobile-based biomarker solutions in clinical trials and patient care further cemented their market leadership. Healthcare businesses reap the benefits of strategic alliances with technology businesses, educational institutions, and healthcare services, which promote the widespread deployment of digital neuro biomarkers. The increased frequency of neurodegenerative illnesses, in tandem with supportive policy for digital medicine innovations, increased product advancement as well as marketing.

Speak with Our Expert Analyst Today to Gain Deeper Insights @
https://www.snsinsider.com/request-analyst/5498

North America dominated the digital neuro biomarkers market with a 35% market share in 2023

The dominance is due to its well-established health infrastructure, high use of cutting-edge medical technologies, and strong establishment of major players in the market. The region enjoys huge investments in digital health solutions, large-scale research activities, and favorable regulatory frameworks fostering innovation. Moreover, the growing incidence of neurological diseases, including Alzheimer's and Parkinson's, and rising awareness regarding early detection

and disease monitoring have fueled the use of digital neuro biomarkers among hospitals, research centers, and healthcare organizations.

The Asia-Pacific region is likely to experience the fastest growth in the digital neuro biomarkers market owing to rising healthcare spending, high-speed technological developments, and an aging population prone to neurological diseases. The growing digital health ecosystem of the region, combined with increasing smartphone penetration and AI-powered healthcare applications, is propelling market uptake.

Buy Full Research Report on Digital Neuro Biomarkers Market 2024-2032 @ https://www.snsinsider.com/checkout/5498

About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Jagney Dave
SNS Insider Pvt. Ltd
+1 315 636 4242
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram

This press release can be viewed online at: https://www.einpresswire.com/article/788038965